Evidence map›Paper›PMID 30993651›Full record

ReviewDrugs2019

Lenvatinib: A Review in Hepatocellular Carcinoma.

Zaina T Al-Salama, Yahiya Y Syed, Lesley J Scott

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04656249 (The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer), which is not on this map. Cited by 206 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 7 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04656249 phase2completednot on this map

The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer

TypeinterventionalSponsorPeking Union Medical College HospitalRan2018 to 2021Enrolled46ConditionsCholangiocarcinoma, Biliary Tract Cancer, Targeted TherapyArmsLenvatinib
3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 7 syntheses or guidelines pooled it, 321 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zaina T Al-SalamaSpringer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Yahiya Y SyedSpringer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Lesley J ScottSpringer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Springer Nature (New Zealand) · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib (Lenvima

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularDose-Response Relationship, DrugHumansLiver NeoplasmsPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesSorafenibTreatment OutcomeTyrosineAntineoplastic AgentslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesSorafenibTyrosine

Identifiers

PMID30993651
OpenAlexW2935887716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.